NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
NK CellTech will use this funding to research and develop natural killer cell therapy pipelines.
NK CellTech is a cell therapy company that focuses on natural killer cell therapy R&D and technology transfer. The company aims to provide immunotherapy to many patients more safely and effectively. NK CellTech has developed a wide range of technology and products based on natural killer cell therapy technology, which is the company's primary area of focus.
The company has a world-class R&D team with more than 30 years of experience in cell therapy research. The team has dedicated itself to immunotherapy innovation for creating NK cells that satisfy various clinical requirements by leveraging immunological techniques such as logical circuits and intelligent control and using genetic engineering to intellectualize cell therapy quantitatively.
According to Yi Zhang, a partner at Huagai Capital Co, they are optimistic about the future of innovative cellular therapeutics, which has always been a key focus area. The advantages of NK cells include their high druggability, low side effects, and high clinical potential.
NK CellTech and ZhiGang Tian, the company's founders and a fellow of the Chinese Academy of Engineering, have spent decades developing a deep understanding and strategic vision of cell therapy. Huagai Capital Co values NK CellTech's work and will continue to support their endeavor to assist more cancer patients.